Agios Pharmaceuticals (AGIO)

• Market cap: $2.34B
• 1 day: -1.66%
• 5 days: -1.85%
• 1 month: 10.85%
• 3 months: 2.57%
• 6 months: 46.22%
• Year to date: 26.38%
• 1 year: -2.52%
• 5 years: 10.55%
• 10 years: -43.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Employees: 488